Cargando…

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study

INTRODUCTION: There is scarce data regarding the incidence of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in the molecular subtypes of non-small cell lung cancer (NSCLC). We aimed to investigate the association between Anaplastic Lymphoma Kinase (ALK)-positive NSCLC and thromboem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Icht, Oded, Leader, Avi, Batat, Erez, Yosef, Lilach, Shochat, Tzippy, Goldstein, Daniel A, Dudnik, Elizabeth, Spectre, Galia, Raanani, Pia, Hammerman, Ariel, Zer, Alona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243788/ https://www.ncbi.nlm.nih.gov/pubmed/37014824 http://dx.doi.org/10.1093/oncolo/oyad061

Ejemplares similares

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
por: Sharman Moser, Sarah, et al.
Publicado: (2022)

Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants—A Retrospective Cohort Study
por: Ayalon-Dangur, Irit, et al.
Publicado: (2021)

Arterial Thromboembolism in Patients With AF and CHA(2)DS(2)-VASc Score 0-2 With and Without Cancer
por: Leader, Avi, et al.
Publicado: (2023)

Challenges and Advances in Managing Thrombocytopenic Cancer Patients
por: Leader, Avi, et al.
Publicado: (2021)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
por: Simon, Michael, et al.
Publicado: (2018)

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature
por: Averbuch, Itamar, et al.
Publicado: (2023)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy
por: Rotem, Ofer, et al.
Publicado: (2023)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study
por: Gershman, Evgeni, et al.
Publicado: (2020)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

SEATED-IMMOBILITY THROMBOEMBOLISM SYNDROME COMPLICATING CORONAVIRUS DISEASE 2019 OUTBREAK QUARANTINE
por: Ali, Abdulla, et al.
Publicado: (2020)

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review
por: Xiong, Wei, et al.
Publicado: (2023)

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non‐Small Cell Lung Cancer in U.S. Community Medical Centers
por: Bernicker, Eric H., et al.
Publicado: (2021)

Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study
por: Moore, Assaf, et al.
Publicado: (2020)

Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models
por: Raghu, Vineet K, et al.
Publicado: (2019)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Is asymptomatic postoperative venous thromboembolism associated with long-term survival in patients undergoing lung resection for malignancy?
por: Akhtar-Danesh, Gileh-Gol, et al.
Publicado: (2021)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
por: Geiger, Karyn Revital, et al.
Publicado: (2022)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Seasonal Changes in the Incidence of Transient Global Amnesia
por: Keret, Ophir, et al.
Publicado: (2016)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

P657: PATHOGENESIS OF TYROSINE KINASE INHIBITOR–ASSOCIATED VASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA
por: Gover Proaktor, Ayala, et al.
Publicado: (2023)

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course
por: Tschernichovsky, Roi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_14tesb4s40dkarcf2608pia53k